Adjuvent

RTOG 0413/B-39:

Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) versus Partial Breast Irradiation (PBI) for Women with Stage 0, I or II Breast Cancer. RTOG 0413/B-39 Clinical Abstract (PDF)

NSABP B-43:

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy. NSABP B-43 Clinical Abstract (PDF)

NSABP B-47:

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel to Chemotherapy) plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer. NSABP B-47 Clinical Abstract (PDF)

S1007:

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2 Negative Breast Cancer with Recurrence Score (RS) of 25 or less. S1007 Clinical Abstract (PDF)

Metastatic

E2108:

A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer. E2108 Clinical Abstract (PDF)

 

 

Phyllodes Tumor

D0929:

A prospective Study of Partial Breast Adjuvant Radiation Therapy After Resection of Borderline and Malignant Phyllodes Tumors

 

 

Metastatic

There are no trials at this time.

Adjuvant

CALGB 80702:

A Phase III Trial of 6 versus 12 Treatments of Adjusted Folfox plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer. CALGB 80702 Clinical Abstract (PDF)

Adjuvant

E1505:

A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely Resected Stage IB (> 4 cm) - IIIA Non Small Cell Lung Cancer (NSCLC). E1505 Clinical Abstract (PDF)

S0819:

A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carbolpatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). S0819 Clinical Abstract (PDF)

E5508:

A Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC. E5508 Clinical Abstract (PDF)

E6508:

A Phase II Study L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer after Definitive Chemoradiation. E6508 Clinical Abstract (PDF)

E2903:

Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed By Campath-1H for Previously Treated Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia. E2903 Clinical Abstract (PDF)

E3903:

Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered forECOG Treatment Trials for Leukemia or Related Hematologic Disorders. E3903 Clinical Abstract (PDF)

E1908:

A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab. E1908 Clinical Abstract (PDF)

C50303:

Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas. C50303 Clinical Abstract (PDF)

E3A05:

Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for Studies of Plasma Cell Disorders. E3A05 Clinical Abstract (PDF)

C90802:

Randomized Phase III Trial Comparing Everolimus Plus Placebo Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors. C90802 Clinical Abstract (PDF)

CTP-2:

Intensity Modulated Radiation Therapy Followed by Cesium-131 Brachytherapy for Intermediate and high Risk Localized Prostate Cancer. CTP-2 Clinical Abstract (PDF)

E2905:

A Randomized Phase III Trial Comparing the Frequency of major Erythroid Response (MER) to Treatment with Lenalidomide (revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia. E2905 Clinical Abstract (PDF)

There are no trials at this time.

E1609:

A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma. E1609 Clinical Abstract (PDF)

There are no trials at this time.